TEL-AVIV, Israel, Dec.
21, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL)
(“RedHill” or the “Company”), a biopharmaceutical company primarily focused on
the development and commercialization of late clinical-stage, proprietary, orally-administered,
small molecule drugs for gastrointestinal and inflammatory diseases and cancer,
today announced that it intends to offer its American Depositary Shares
(“ADSs”), each representing ten of its ordinary shares, and warrants to
purchase ADSs, concurrently in an underwritten public offering and in a
registered direct offering. RedHill also expects to grant the underwriters a
30-day option to purchase up to an additional 15% of the securities offered to
the public in the underwritten public offering. Both offerings are subject to
market conditions and there can be no assurance as to whether or when the
offerings may be completed, or as to the actual size or terms of the offerings.
Source : RedHill
Biopharma Ltd.
No comments:
Post a Comment